Colorado-based biotech company Next Frontier Biosciences (“NFB”) announced plans to launch a suite of purified cannabinoid products for the medical and adult-use marijuana markets in Colorado in the third quarter of 2017. NFB’s Verra Wellness line of products are scientifically formulated for accurate and consistent delivery of purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in three different ratios via nasal mists and sublingual sprays. Verra Wellness will also offer a line of small batch topical salves designed to permeate skin and muscle tissue deeply without penetrating the blood stream or causing psychoactive effects.

“Next Frontier Biosciences’ Verra Wellness line of nasal, sublingual and topical products will provide cannabis patients and consumers with important alternatives to smoking, vaporizing or eating impure and poorly characterized cannabis products,” said Marc Graboyes, NFB’s co-founder and Chief Executive Officer. “We plan to launch in Colorado in the third quarter of this year and will seek to expand into the 10 legal state markets by 2020. Our team of highly experienced research scientists will also continue enhancing and expanding our product offerings by incorporating new cannabinoids and developing additional product lines with a focus on improved absorption, or bioavailability.”

“Cannabinoids are the primary active ingredients in the cannabis plant and have demonstrated a wide range of therapeutic benefits for the treatment of chronic pain, anxiety, insomnia and post-traumatic stress disorder, among other conditions,” continued Dr. Paul Johnson, Ph.D., NFB’s co-founder and Chief Scientific Officer. “At Next Frontier Biosciences, we believe that cannabinoid purification and scientific formulation are the keys to unlocking the power of the plant and developing safer and more effective cannabinoid-based products. We are reshaping the cannabis industry by designing a premium brand of trusted cannabis infused products that provide uniform composition, formulation and dosing in several discreet and highly consistent modes of administration.”

Founded in 2014, NFB has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. NFB’s proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.

“Next Frontier Biosciences is structured as an intellectual property and brand management company,” explained Mr. Graboyes. “We operate primarily through strategic collaborations with third parties who hold the licenses and approvals required to develop, manufacture and distribute our cannabis-infused products in their respective state markets. As such, we are actively seeking strategic partners to help bring our products to market in other states and countries throughout the world.”

Mr. Graboyes will speak at the National Cannabis Industry Association Cannabis Business Summit & Expo (June 12-14, 2017, Oakland Marriott City Center, Oakland, California) on the panel discussion “Unveiling The Future: A New Crop of Infused Products” on Tuesday, June 13 at 2:45pm. Mr. Graboyes will discuss NFB’s scientific approach to cannabis product development and future innovation.

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.

About Next Frontier Biosciences:

Next Frontier Biosciences (NFB) is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, NFB is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. NFB’s goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.

NFB is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., NFB’s co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.

Dr. Paul Johnson, Ph.D., NFB’s co-founder and Chief Scientific Officer, is responsible for leading the development and implementation of the company’s research and development programs, advising the company on scientific matters, evaluating data, and overseeing the company’s intellectual property strategy and patent portfolio. Dr. Johnson has over four decades of pharmaceutical industry experience and is a leading expert in the field of intranasal drug development and delivery systems. Prior to joining the company, he served as Chief Scientific Officer of PhaseRx Pharmaceuticals, Nastech Pharmaceuticals, and EpiGenX Pharmaceuticals. Prior to that, he held scientific leadership roles with Berlex Biosciences and SRI International. During his career, Dr. Johnson has authored over 100 patents and scientific publications, as well as two books on pharmaceutical discovery and development.

Dr. Dorothy “Dot” Colagiovanni, Ph.D., NFB’s Senior Director, Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decade of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivilas Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch.

For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.